Advertisement

Topics

ASCO highlights: Bevacizumab for relapsed ovarian cancer

10:30 EDT 12 Jul 2018 | ecancermedicalscience

Prof Ledermann speaks with ecancer at BCGS 2018 about results from ASCO 2018 showing improved response rate and PFS for platinum-refractory patients who received second-line therapy with additional bevacizumab. He considers what this means for global...

Original Article: ASCO highlights: Bevacizumab for relapsed ovarian cancer

NEXT ARTICLE

More From BioPortfolio on "ASCO highlights: Bevacizumab for relapsed ovarian cancer"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...